Status:
COMPLETED
Performance Comparison Between Masimo W1™ and Apple Watch Series 8
Lead Sponsor:
Masimo Corporation
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Brief Summary
This study is also designed to compare the performance of Masimo W1™ and Apple Watch Series 8 against FDA cleared hospital grade pulse oximetry technology under desaturation conditions.
Eligibility Criteria
Inclusion
- Subject is 18 to 55 years of age.
- Subject is American Society Anesthesiologist status 1 (ASA I)
- Subject has a BMI between 18 and 35.
- Subject is able to read and communicate in English and understands the study and the risks involved.
Exclusion
- Subject is currently taking any medications which in the opinion of the principal investigator would not be suitable for participation in the study.
- Subject is wearing nail polish that cannot be removed, gel nails, and/or acrylic nails that can interfere with study device's placement.
- Participants with conditions or skin abnormalities at or around site of sensor placement that could affect the placement on the sensor or prevent monitoring of physiological parameters during the study, such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown.
- Subject has participated in an investigational drug study within one month prior to the start of the study.
- Subject has failed the Allen's Test to confirm patency of the collateral artery.
- Subject is female with a positive pregnancy test, or is female and is unwilling to use effective birth control between the time of screening and study termination.
- Subject has a positive urine cotinine or drug test.
- Subject has a reported allergy to Lidocaine.
- Subject has clinically significant anemia or other hemoglobinopathy.
- Subject has a room air saturation of less than 95% by pulse oximetry.
- Subject has a clinically significant abnormal EKG.
- Subject has a clinically significant abnormal pulmonary function test via spirometry.
- Subject is intolerant to a breathing mask apparatus.
- Subject has a COHb greater than 3%, or MetHb greater than 2% verified by laboratory co-oximeter.
- Subject has another condition, which in the opinion of the principal investigator would not be suitable for participation in the study.
- Subject is unwilling or unable to provide informed consent or comply with the study procedures.
Key Trial Info
Start Date :
September 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 11 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05968079
Start Date
September 6 2023
End Date
October 11 2023
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Human Pharmacology and Physiology Laboratory (HPPL) - Duke University Medical Center
Durham, North Carolina, United States, 27705